Lentris 10mg Capsule contains Lenvatinib, a potent multi-kinase inhibitor used primarily in the treatment of various malignancies including differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma. Lenvatinib exerts its therapeutic effects by selectively inhibiting vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT signaling pathways, thereby impeding tumor angiogenesis and proliferation. Lentris is indicated for patients with progressive, radioactive iodine-refractory differentiated thyroid cancer and as first-line treatment in combination with everolimus for advanced renal cell carcinoma following one prior anti-angiogenic therapy. The recommended dosage is 10 mg orally once daily, with adjustments based on patient tolerance and adverse effects. Common adverse reactions include hypertension, fatigue, diarrhea, decreased appetite, and proteinuria, necessitating regular monitoring of blood pressure, liver function, and renal parameters during therapy. Dose modifications or temporary discontinuation may be required in cases of severe toxicity. Lentris should be prescribed and administered under the supervision of an oncologist experienced in cancer therapeutics. Patients are advised to adhere strictly to prescribed dosing and report any unusual symptoms promptly to optimize treatment outcomes and minimize risks.